Skip to content
Screener

CytomX Therapeutics CTMX Financing Cash Flow

Financing Cash Flow at other companies

Pfizer logo
PfizerPFE
-$2.86B+45.4%
Amgen logo
AmgenAMGN
-$1.48B+44.6%
Janux Therapeutics logo
Janux TherapeuticsJANX
$2.24M+135%
Immunome logo
ImmunomeIMNM
$1.06M
Arcus Biosciences logo
Arcus BiosciencesRCUS
$16M-69.2%
CTO
Citius Oncology, Inc.CTOR
$15.13M+299%

Other financials

Income statement

See full
Revenue$1.4M-92.4%
Operating income-$23.8M-1,749%
Net income-$20.7M-13,319%
EPS (diluted)-$0.09

Balance sheet

See full
Cash & equivalents$17.2M-64.9%
Total debt$5.7M-17.2%
Total equity$302.1M+152%
Total assets$381.2M+118%

Cash flow

See full
Operating cash flow-$18.1M-14.7%
CapEx--100%
Free cash flow-$18.1M-14.5%

Valuation

See full
Market cap$749.57M+96.8%
Enterprise value$738.05M+118%
P/S41×+38.3×

Profitability

See full
Operating margin-476.2%-507pp
Net margin-435.2%-469pp
FCF margin-450.7%-524pp

Returns & leverage

See full
Return on equity-37.8%
Debt / equity0.0×
Current ratio9.4×+5.2×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-337950
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Proceeds from issuance of pre-funded warrants, net of issuance cost5,855
Proceeds from issuance of common stock, net of issuance cost228,40793,373
Proceeds from employee stock purchase plan and exercise of stock options736177
Net cash provided by financing activities234,99893,550
Net increase in cash, cash equivalents and restricted cash4,55710,990
Cash, cash equivalents and restricted cash, beginning of period14,19439,079
Cash, cash equivalents and restricted cash, end of period$18,751$50,069
Supplemental disclosures of noncash financing activities:

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is CytomX Therapeutics's financing cash flow?
CytomX Therapeutics (CTMX) reported financing cash flow of $511K in Q2 2026.
How has CytomX Therapeutics's financing cash flow changed year-over-year?
CytomX Therapeutics's financing cash flow decreased by 99.5% year-over-year, from $93.55M to $511K.
What is the long-term trend for CytomX Therapeutics's financing cash flow?
Over 4 years (2021 to 2025), CytomX Therapeutics's financing cash flow has grown at a 0.1% compound annual growth rate (CAGR), from $110.21M to $110.45M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about CytomX Therapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude